SCHEMBL4166291

SCHEMBL4166291

COc1cccc(-c2ncccc2CC(=O)O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 1/20 0.59
DYRK1A Q13627 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
LMNA P02545 2/20 0.48
PDE4A P27815 2/20 0.47
PDE4B Q07343 2/20 0.47
PDE4C Q08493 2/20 0.47
PDE4D Q08499 2/20 0.47
HSD17B10 Q99714 1/20 0.47
RECQL P46063 1/20 0.46
PTGDR2 Q9Y5Y4 2/20 0.46
CTSA P10619 1/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP1A2 P05177 1/20 0.46
MAPT P10636 1/20 0.46
VDR P11473 1/20 0.45
PPARD Q03181 1/20 0.45
DHODH Q02127 1/20 0.45
KMT2A Q03164 1/20 0.45
RXRA P19793 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16047508 0.85 KCNA5 (0.62) KCNA5DYRK1ACLK4LMNAPDE4A
SCHEMBL17084669 0.81 KCNA5 (0.60) KCNA5DYRK1ACLK4LMNAPDE4A
SCHEMBL16047875 0.81 KCNA5 (0.60) KCNA5DYRK1ACLK4LMNAPDE4A
SCHEMBL8491910 0.80 KDM4E (0.59) KCNA5LMNAPTGDR2KDM4ECYP1A2
SCHEMBL22160863 0.80 DHODH (0.59) KCNA5DYRK1ACLK4LMNAPDE4A
SCHEMBL30832877 0.80 DHODH (0.59) KCNA5DYRK1ACLK4LMNAPDE4A
SCHEMBL4052652 0.80 PTGDR2 (0.47) LMNAHSD17B10RECQLPTGDR2CTSA
SCHEMBL4055913 0.80 LMNA (0.46) KCNA5DYRK1ACLK4LMNARECQL
SCHEMBL4055920 0.79 LMNA (0.51) LMNAHSD17B10KDM4ECYP1A2MAPT
SCHEMBL6174210 0.76 JAK2 (0.56) DYRK1ACLK4PDE4BRECQLKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209571-A1 Phenanthrene derivatives as MPGES-1 inhibitors CELLUMEN INC. 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209571-A1 Phenanthrene derivatives as MPGES-1 inhibitors PTGES, PTGS1, PTGES2 KCNA5 2377/4885DYRK1A 4646/4885CLK4 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.